Saturday 17 October 2026 Export PVLA’s income statement to Excel — free account

Palvella Therapeutics, Inc.

In the quarter to June 2026, EPS fell 76.7% and free cash flow fell 136.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

120.30 7.04 −5.53%

Follow PVLA

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 2/9
Altman Z: −11.49
Beneish M: 1.44
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.85

Total sells 13.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	2	1	—	—	—	—	—	—	—
Sell	1	1	1	1	1	1	1	1	1	1	3	1

Insider Ownership 36.33%

Capital & Financial Ratios $m

Market Cap 1,830.00

Revenue 41.56

Net Income (61.70)

Free Cash Flow (36.51)

Net Debt (250.58)

Current Ratio 21.18

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.34)

P/S ratio 41.55

P/B ratio 7.96

Past 5Y EPS Growth —

This Y EPS Growth (77.85%)

Next Y EPS Growth (25.56%)

Next Y revenue growth (53.67%)

Next 5Y EPS Growth (19.52%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 97.09%

10-year low 10-year high

P/B against its own 10 years 78.17%

10-year low 10-year high

EV/Sales against its own 10 years 96.61%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	7	84	58	251
Receivables	6	2	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	8	88	59	253

	2023	2024	2025	Q'26
Payables	1	5	5	7
ST’ Debt	—	—	—	—
Other	—	2	2	—
	2	12	11	12

Compound Annual Growth %

	10y	5y	3y
Sales	13.17%	8.03%	13.44%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(1.06%)	(2.04%)	0.06%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	20	20	—	—
’22	11	4	5	6	26
’21	16	3	4	8	31
’20	13	11	3	2	29
’19	9	5	15	17	46
’18	4	12	8	5	29
’17	1	2	4	18	25

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(13)	—	—	—
’25	(7)	(5)	(8)	(5)	(25)
’24	(1)	(2)	(3)	(5)	(11)
’23	(11)	(13)	(10)	20	(14)
’22	(23)	(16)	(9)	(13)	(60)
’21	(12)	30	(14)	(11)	(8)
’20	(15)	(10)	(8)	(13)	(46)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(13)	—	—	—
’25	(7)	(5)	(8)	(5)	(25)
’24	(1)	1	0	(5)	(11)
’23	(11)	(13)	(10)	20	(14)
’22	(23)	(16)	(9)	(13)	(61)
’21	(12)	30	(15)	(11)	(9)
’20	(17)	(11)	(7)	(14)	(49)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.20)	(1.52)	—	—	—
’25	(0.74)	(0.86)	(1.03)	(1.08)	(3.71)
’24	(1.43)	(2.76)	(3.83)	(0.21)	(7.83)
’23	(14.40)	4.00	(8.80)	(3.20)	(21.60)
’22	(5.60)	(11.20)	(10.40)	(8.80)	(36.00)
’21	(5.60)	(20.00)	(19.20)	(10.40)	(56.80)
’20	(5.60)	(7.20)	(20.80)	(20.80)	(54.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	100.80	110.40	191.20	195.20	128.00	136.00	67.68	10.88	6.20	11.28	Analyst estimates 2026–2028 Powerpack
	High	198.40	619.20	780.00	483.20	344.00	492.00	326.08	157.60	22.32	114.69
People
People	Employees	52	68	116	127	123	141	144	50	14	29
	Revenue/emp, $m	0.11	0.37	0.25	0.36	0.24	0.22	0.18	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	6	25	29	46	29	31	26	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—
	EBT	(23)	(17)	(27)	(25)	(37)	(46)	(33)	19	(17)	(42)
	EBT margin, %	(388.22)	(65.46)	(93.01)	(55.03)	(126.41)	(145.58)	(128.47)	0.00	0.00	0.00
	Net income	(23)	(18)	(27)	(25)	(37)	(46)	(33)	19	(17)	(42)
	Depreciation	0	0	1	1	2	2	3	—	—	—
Per share, $
Per share, $	Revenue	11.18	46.03	43.86	73.13	43.06	38.94	27.94	0.00	0.00	0.00
	Earnings	(44.00)	(32.00)	(40.00)	(44.80)	(54.40)	(56.80)	(36.00)	(21.60)	(7.83)	(3.71)
	Cash flow	(27.59)	90.61	(1.61)	(82.91)	(67.39)	(9.49)	(64.64)	(7.74)	(4.87)	(2.22)
	Capex	(1.07)	(3.55)	(2.56)	(3.89)	(4.00)	(1.18)	(1.12)	(0.10)	0.00	0.00
	Free cash flow	(28.67)	87.06	(4.17)	(86.80)	(71.40)	(10.67)	(65.76)	(7.84)	(4.87)	(2.22)
	Book value	48.38	20.98	60.19	81.15	45.56	62.91	30.12	(2.19)	28.13	2.49
	Shares, m	1	1	1	1	1	1	1	2	2	11
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	P/S	10.44	13.47	4.85	3.96	4.64	7.77	3.12	0.62	—	—
	P/B	2.41	29.55	3.54	3.57	4.39	4.81	2.89	0.00	—	—
	EV/Sales	5.63	10.65	0.49	1.74	2.29	4.06	0.89	0.47	—	—
	EV/FCF	(2.20)	5.63	(5.19)	(1.46)	(1.38)	(14.81)	(0.38)	(1.46)	—	—
Cash, $m
Cash, $m	Operating cash flow	(14)	50	(1)	(52)	(46)	(8)	(60)	(14)	(11)	(25)
	Capex	(1)	(2)	(2)	(2)	(3)	(1)	(1)	0	—	—
	Free cash flow	(15)	48	(3)	(55)	(49)	(9)	(61)	(14)	(11)	(25)
Balance, $m
Balance, $m	Working capital	24	44	87	88	54	77	37	5	76	48
	Total debt	—	—	—	16	17	15	13	—	—	—
	Net debt	(29)	(73)	(128)	(104)	(70)	(118)	(59)	(7)	(84)	(58)
	Shareholders’ equity	25	12	40	51	31	51	28	(4)	63	28
Returns, %
Returns, %	ROA	(66.07)	(25.40)	(21.82)	(20.04)	(30.26)	(35.38)	(26.72)	7.54	(36.40)	(56.45)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(80.91)	(96.04)	(103.99)	(62.00)	(90.39)	(111.85)	(84.58)	(16.69)	293.60	(92.10)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MLYS Mineralys Therapeutics, Inc.	$1.9B	— (loss-making)	—	—	n/m	−7.91% (below 0%: shrinking)	—	0.00%	Compare
SRPT Sarepta Therapeutics, Inc.	$1.9B	— (loss-making)	4.4×	−34.34% (below 0%: shrinking)	n/m	−14.48% (below 0%: shrinking)	62.77%	3.31%	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
ZYME Zymeworks Inc.	$1.8B	— (loss-making)	16.2×	−90.58% (below 0%: shrinking)	n/m	−385.53% (below 0%: shrinking)	(497.71%)	(918.95%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%	Compare
XNCR Xencor, Inc.	$1.8B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
VIR Vir Biotechnology, Inc.	$1.8B	— (loss-making)	— (loss-making)	+19,582.54% (above 0%: growing)	n/m	+200.47% (above 0%: growing)	100.00%	30.75%	Compare
Median of peers	$1.8B	—	—	+8.53%	—	−11.20%	62.77%	(14.66%)

All 614 Biotechnology stocks →

Palvella Therapeutics, Inc. (PVLA) key facts

Palvella Therapeutics, Inc. (PVLA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PVLA traded at $120.30, a market capitalization of $1.8 billion.
Return on equity was −92.1% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −11.49 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.